Sircar, Ila published the artcileNonpeptide angiotensin II receptor antagonists. 2. Design, synthesis, and structure-activity relationships of 2-alkyl-4-(1H-pyrrol-l-yl)-1H-imidazole derivatives: profile of 2-propyl-1-[[2′-(1H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl]-methyl]-4-[2-(trifluoroacetyl)-1H-pyrrol-1-yl]-1H-imidazole-5-carboxylic acid (CI-996), Synthetic Route of 5098-14-6, the publication is Journal of Medicinal Chemistry (1993), 36(16), 2253-65, database is CAplus and MEDLINE.
A novel series of nonpeptide angiotensin II (AII) receptor antagonists containing a 1H-pyrrol-1-yl moiety at the 4-position of the imidazole have been developed. The pyrrole group occupies the same lipophilic pocket at the receptor as the chloro group in DuP 753 and EXP 3174 (I; R = Bu, R1 = CH2OH, CO2H, R2 = Cl, resp.) and the pentafluoro group in DuP 532 (I; R = Pr, R1 = CO2H, R2 = CF2CF3). The impetus for its selection came from bioisosteric considerations based on hydrophobic and electronic substituent constants An extensive study of the structure-activity relationships revealed several highly potent AII receptor antagonists. An acyl substitution at the 2-position of the pyrrole ring improved activity, most notably in the in vivo rat model. In addition, the 2-substituted pyrrole compounds improved chem. stability toward extremely facile decarboxylation reaction associated with unsubstituted pyrrole analogs, thus facilitating development of these agents. The IC50‘s of I [R = Pr, R1 = CO2H, R2 = 2-(trifluoroacetyl)- (18), 2,5-dimethyl-, or 2,5-dichloro-1H-pyrrol-1-yl] (<1 nM) were better than the reference compounds EXP 3174 and DuP 532. These compounds were selective AII antagonists that compete at the AT1 receptor and showed no affinity at the AT2 receptor at concentrations up to 10 M. Upon i.v. administration in a normotensive rat model, compound 18 inhibited the AII-induced responses with ED50 of 6 g/kg per min. In a renal hypertensive rat model, the antihypertensive potency of compound 18, at a dose of 10 mg/kg, was very similar to those of DuP 753 and EXP 3174, resp. Compound 18 demonstrated a dose-related (3-30 mg/kg) decrease in blood pressure that was sustained for greater than 24 h. On the basis of its profile, compound 18, designated as CI-996, has been selected for in-depth studies. The design, synthesis, in vitro, and in vivo structure-activity relationships are described.
Journal of Medicinal Chemistry published new progress about 5098-14-6. 5098-14-6 belongs to nitriles-buliding-blocks, auxiliary class Nitrile,Salt,Sulfonic acid,Amine,Benzene, name is 2-Aminomalononitrile 4-methylbenzenesulfonate, and the molecular formula is C6H16OSi, Synthetic Route of 5098-14-6.
Referemce:
https://en.wikipedia.org/wiki/Nitrile,
Nitriles – Chemistry LibreTexts